year
year202420232022all
Corporate Update

New operating unit of BIOGENERA SpA in Paris in the prestigious Paris Saclay Cancer Cluster (PSCC)

BIOGENERA SpA is in the process of finalizing the establishment of a new operating unit of the Company in Paris. After a period of careful evaluation for the most appropriate choice, the final decision was made for the Paris Saclay Cancer Cluster (PSCC)(https://www.parissaclaycancercluster.org). The Paris Saclay Cancer Cluster is located in Paris, in the Villejuif […]

Read More…

Corporate Update

A New Goal for Biogenera: BGA002, the Future of Cancer Therapy

The Biogenera team has achieved a major breakthrough in the development of the innovative anti-tumor drug BGA002: a revolutionary drug that targets aggressive tumors in both children and adults, specifically targeting cancer cells and sparing healthy ones. An Innovation in the Fight Against Cancer. New scientific data show that BGA002 is able to penetrate and […]

Read More…

Event

BIOGENERA will participate in the Bio Europe Spring in Barcelona

BIOGENERA SpA will attend the Bio Europe Spring international congress to be held in Barcelona on March 18, 19 and 20, 2024. Building on the success of EBD Group’s flagship conference, BIO-Europe┬«, BIO-Europe Spring will bring together more than 3,700 top executives from around the world. More than 20,000 meetings of potential partnerships will take […]

Read More…

Corporate Update

NewCap is chosen as the new investor relations firm for BIOGENERA

News Body: An agreement has been signed with NewCap, a French Investor Relation company, which will be in charge of managing BIOGENERA SpA’s official communications as of its listing on Euronext Paris. NewCap was selected because it has extensive experience in Investor Relations (IR) of companies listed on the Paris Euronext exchange, including companies in […]

Read More…

Event

BIOGENERA participated in the International Congress on Neuroblastoma ANR (Advances in Neuroblastoma Research) held in Amsterdam May 15-18, 2023

The congress was attended by more than 800 researchers from around the World. Preclinical data of BIOGENERA’s new anti-tumor drug BGA002 were presented, and the new Phase I clinical trial for Neuroblastoma that will be initiated in the coming months was also presented. The data attracted great interest and attention. The Congress was an opportunity […]

Read More…

Corporate Update

Thibaud Eckenschwiller has been appointed president of BIOGENERA, May 2023

On May 2, 2023, BIOGENERA’s shareholders’ meeting approved the 2022 budget; the new Board of Directors (BOD) was also appointed on this occasion. Dr. Thibaud Eckenschwiller has been appointed chairman of the board of BIOGENERA. Dr. Eckenschwiller is a top manager in the pharmaceutical industry with extensive international experience. Dr. Eckenschwiller is Senior Life Sciences […]

Read More…

Corporate Update

Giacinto d’Ettorre becomes board member of BIOGENERA

Dr. Giacinto d’Ettorre has been appointed as a new board member of BIOGENERA. Dr. D’Ettorre has many years of experience in the pharmaceutical industry at management levels. He currently serves as chief financial officer (CFO) at a leading pharmaceutical company, and previously served as CFO of Europe at SHIRE (now merged into TAKEDA), and CFO […]

Read More…

Search

Patent Approval in Argentina

Regarding patents held by BIOGENERA, a patent has been granted outright in Argentina. This brings to a total of 56 fully-owned BIOGENERA patents that are approved outright, covering 46 countries globally, covering the MyGeneraTM platform, the drug BGA002 and five other drug candidates. […]

Read More…

Corporate Update

The company ComputerShare has been chosen to manage the corporate structure of BIOGENERA.

BIOGENERA has signed an agreement with Computershare Italia, which is part of Computershare Limited, the leading stock transfer company that provides corporate trust, stock transfer and employee stock plan services in numerous countries. Computershare will mainly deal with the dematerialization of shares at MonteTitoli and other activities related to the management of shares since the […]

Read More…

Search

BIOGENERA has reached a new milestone in lung cancer treatment

An important achievement has been achieved by the BIOGENERA Research Team regarding the scientific publication of a new article in the prestigious international journal “Cancers.” The article titled “Antigen MYCN Silencing by BGA002 Inhibits SCLC Progression Blocking mTOR Pathway and Overcomes Multidrug Resistance” describes the anti-tumor efficacy obtained in preclinical studies related to our new […]

Read More…

Search

MYCN is a key target for cases of High-Risk Neuroblastoma

An important achievement was achieved, concerning the publication of an article in the prestigious international journal “Cancers” entitled “MYCN Impact on High-Risk Neuroblastoma: From Diagnosis and Prognosis to Targeted Treatment” regarding the centrality of the MYCN oncogene in the pathological context of neuroblastoma. Specifically, the study highlights how MYCN affects High Risk Neuroblastoma cases, in […]

Read More…

Corporate Update

Mario Nespoli is the new CFO of BIOGENERA

BIOGENERA has appointed as the company’s new chief financial officer (CFO) Dr. Mario Nespoli, who has many years of experience in the pharmaceutical industry at management levels. Dr. Nespoli served as general manager for REYS Spa, where he created a new management team, opened new branches in the European Union, and invested in new production […]

Read More…

Search

Oligonucleotides represent a new frontier for expanding drug targets for targeted cancer treatment

An important achievement has been achieved by the BIOGENERA Research Team regarding the scientific publication of an article in the prestigious international journal “Pharmaceutics.” The article titled “Precision Anti-Cancer Medicines by Oligonucleotide Therapeutics in Clinical Research Targeting Undruggable Proteins and Non-Coding RNAs” is about the importance of precision medicine in oncology. In particular, the study […]

Read More…

Search

New drug BGA002 overcomes Neuroblastoma resistance to Retinoic Acid drug

An important achievement has been achieved by the BIOGENERA Research Team, concerning the scientific publication of an article in the prestigious international journal “Journal of Experimental & Clinical Cancer Research.” The article titled “The MYCN inhibitor BGA002 restores the retinoic acid response leading to differentiation or apoptosis by the mTOR block in MYCN-amplified Neuroblastoma” is […]

Read More…